Literature DB >> 28736381

[Efficacy of ACEI in the treatment of hypertension and the effect of secondary prevention in patients complicated with coronary heart disease and stroke].

Yang Li1, Jun-Fa Liu, Ya-Feng Hao, Xue-Zhi Wang.   

Abstract

OBJECTIVE: To investigate the efficacy of ACEI drugs in the treatment of hypertension patients and the effect of two levels of prevention of hypertension complicated with coronary heart disease and stroke. METHDOS: 210 cases of hypertension patients in our hospital from January 2012 to December 2015 were randomly divided into experimental group and control group, 105 cases in each group. According to the conventional symptomatic treatment, the experimental group was given lisinopril treatment, while control group was given the captopril treatment. Changes of blood pressure parameters and the level of baPWV in two groups were observed before and after treatment coronary heart disease and stroke, recurrence rate and death rate were compared in these two groups.
RESULTS: No significant difference of SBP, DBP, PP and baPWV between two groups before treatment (P>0.05). The indexes of the two groups were significantly decreased after 1 months and 3 months, and the level of patients in the experimental group was lower than that of the control group (P<0.05). The recurrence rate in the experimental group was lower than those in the control group (P<0.05).
CONCLUSIONS: ACEI drugs in the treatment of hypertension can effectively reduce the level of blood pressure, improve arterial elasticity function, reduce the recurrence rate and mortality rate of coronary heart disease and stroke. The effect of antihypertensive and two levels of prevention of hypertension complicated with coronary heart disease and stroke of lisinopril is positive.

Entities:  

Year:  2017        PMID: 28736381      PMCID: PMC6765519     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  11 in total

1.  Heart disease and stroke statistics--2015 update: a report from the American Heart Association.

Authors:  Dariush Mozaffarian; Emelia J Benjamin; Alan S Go; Donna K Arnett; Michael J Blaha; Mary Cushman; Sarah de Ferranti; Jean-Pierre Després; Heather J Fullerton; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Simin Liu; Rachel H Mackey; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Paul Muntner; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Graham Nichol; Latha Palaniappan; Dilip K Pandey; Mathew J Reeves; Carlos J Rodriguez; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Joshua Z Willey; Daniel Woo; Robert W Yeh; Melanie B Turner
Journal:  Circulation       Date:  2014-12-17       Impact factor: 29.690

2.  Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.

Authors:  Salim Yusuf; Shofiqul Islam; Clara K Chow; Sumathy Rangarajan; Gilles Dagenais; Rafael Diaz; Rajeev Gupta; Roya Kelishadi; Romaina Iqbal; Alvaro Avezum; Annamarie Kruger; Raman Kutty; Fernando Lanas; Liu Lisheng; Li Wei; Patricio Lopez-Jaramillo; Aytekin Oguz; Omar Rahman; Hany Swidan; Khalid Yusoff; Witold Zatonski; Annika Rosengren; Koon K Teo
Journal:  Lancet       Date:  2011-08-26       Impact factor: 79.321

3.  miR-155 functions downstream of angiotensin II receptor subtype 1 and calcineurin to regulate cardiac hypertrophy.

Authors:  Yong Yang; Yong Zhou; Zheng Cao; Xin Zhu Tong; Hua Qiang Xie; Tao Luo; Xian Ping Hua; Han Qin Wang
Journal:  Exp Ther Med       Date:  2016-07-05       Impact factor: 2.447

4.  Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan.

Authors:  Yusuke Sakamaki; Hiroyuki Sasamura; Shunya Ikeda; Naoki Ikegami; Takao Saruta
Journal:  Hypertens Res       Date:  2006-05       Impact factor: 3.872

5.  Hypertension and hyperglycemia and the combination thereof enhances the incidence of chronic kidney disease (CKD) in middle-aged and older males.

Authors:  Ryoma Michishita; Takuro Matsuda; Shotaro Kawakami; Satoshi Tanaka; Akira Kiyonaga; Hiroaki Tanaka; Natsumi Morito; Yasuki Higaki
Journal:  Clin Exp Hypertens       Date:  2017-06-07       Impact factor: 1.749

Review 6.  The role of β-blockers in the management of hypertension: an Asian perspective.

Authors:  B Tomlinson; J J Dalal; J Huang; L P Low; C G Park; A R Rahman; E B Reyes; A A Soenarta; A Heagerty; F Follath
Journal:  Curr Med Res Opin       Date:  2011-03-16       Impact factor: 2.580

7.  Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).

Authors:  E Lonn; S Yusuf; V Dzavik; C Doris; Q Yi; S Smith; A Moore-Cox; J Bosch; W Riley; K Teo
Journal:  Circulation       Date:  2001-02-20       Impact factor: 29.690

8.  [Cardio-vascular risk factors control in elderly patients with peripheral artery disease].

Authors:  Dorota Studzińska; Barbara Gryglewska; Maria Wojnarowska; Joanna Paleń; Bogusław Rudel; Tomasz Grodzicki
Journal:  Przegl Lek       Date:  2016

9.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

Authors:  K M Fox
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

Review 10.  [Hypertension in the acute phase and in the secondary prevention of stroke].

Authors:  Caroline Arquizan
Journal:  Rev Prat       Date:  2004-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.